DURECT Corp (DRRX.OQ)
DRRX.OQ on NASDAQ Stock Exchange Global Market
2.47USD
18 Apr 2018
2.47USD
18 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$2.47
$2.47
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
161,061
161,061
52-wk High
$2.55
$2.55
52-wk Low
$0.74
$0.74
About
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)
Overall
| Beta: | 1.06 |
| Market Cap(Mil.): | $378.74 |
| Shares Outstanding(Mil.): | 153.34 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| DRRX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 199.23 | 33.71 |
| EPS (TTM): | -0.03 | -- | -- |
| ROI: | -15.07 | -0.66 | 13.09 |
| ROE: | -24.78 | -2.84 | 14.92 |
BRIEF-Durect Announces FDA Advisory Committee Meeting For Remoxy Er
* DURECT ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR REMOXY® ER
BRIEF-Durect Corporation Qtrly Earnings Per Share $0.05
* ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND UPDATE OF PROGRAMS
BRIEF-Durect Corp Says Commenced Patient Dosing In A Phase 2A Clinical Trial Of Dur-928
* DURECT CORP SAYS COMMENCED PATIENT DOSING IN A PHASE 2A CLINICAL TRIAL OF DUR-928 IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) - SEC FILING
BRIEF-Durect reports Q3 earnings per share of $0.04
* Durect Corporation announces third quarter 2017 financial results and provides corporate update
BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint
* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint
Competitors
| Price | Chg | |
|---|---|---|
| Hisamitsu Pharmaceutical Co Inc (4530.T) | ¥7,870 | -180.00 |
| Johnson & Johnson (JNJ.N) | $127.72 | -2.82 |
| Pfizer Inc. (PFE.N) | $36.49 | +0.16 |
| Novartis AG (NOVN.S) | CHF77.30 | -1.50 |
| AstraZeneca plc (AZN.L) | 4,988.00 | +23.50 |
| Eli Lilly And Co (LLY.N) | $79.72 | -0.20 |
| Kimberly Clark Corp (KMB.N) | $106.53 | -0.07 |
| Bristol-Myers Squibb Co (BMY.N) | $52.30 | -0.08 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,306.55 | -- |
| Covidien Ltd (COV.N) | -- | -- |
Estimates